On March, 21 Knight Therapeutics Inc. (GUD) Analysts See $0.03 EPS

Knight Therapeutics Inc. (TSE:GUD) Corporate Logo

Earnings report for Knight Therapeutics Inc. (TSE:GUD) is awaited on March, 21., according to Faxor. Analysts forecast $0.03 earnings per share, which is $0.02 down or 40.00 % from 2018’s $0.05 earnings per share. If earnings per share of $0.03 is reported the profit of T_GUD could be $4.29M giving it 62.92 P/E. 0.00 % EPS growth is what Wall Street’s predicts after $0.03 reported EPS previous quarter. GUD hit $7.55 during the last trading session after $0.02 change.Knight Therapeutics Inc. has volume of 251,818 shares. Since March 15, 2018 GUD has 0.00% and is . GUD underperformed by 4.37% the S&P500.

Knight Therapeutics Inc., a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally.The firm is worth $1.08 billion. The company's commercialized products include Impavido, an alkyllysophospholipid analogue drug for the treatment of visceral and cutaneous Leishmaniasis; Movantik for the treatment of opioid induced constipation; AzaSite to treat bacterial conjunctivitis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Flat Tummy Tea, a herbal detox tea; and FOCUSfactor, a dietary supplement.The P/E ratio is 34.79. The Company’s products under development comprise Probuphine to treat opioid addiction; NeurAxon family to treat acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; Iluvien to treat diabetic macular edema; and Netildex to treat ocular inflammation.

More recent Knight Therapeutics Inc. (TSE:GUD) news were posted by Theglobeandmail.com, Theglobeandmail.com and Seekingalpha.com. The first one has “Knight Therapeutics Inc (GUD-T) Quote – The Globe and Mail” as a title and was posted on November 15, 2017. The next is “The week’s most oversold and overbought stocks on the TSX – The Globe and Mail” on December 28, 2018. And last was posted on November 09, 2016, called “Knight Therapeutics: The Outsider CEO You’ve Never Heard Of – Seeking Alpha”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.